Fero Industries, Inc. to Acquire Pyro Pharmaceuticals, Inc.'s Enzyme Identification Methodology under Definitive Agreement

CALGARY, Alberta--(BUSINESS WIRE)--Fero Industries, Inc. (OTCBB: FROI) (the “Company”) is pleased to announce that it is acquiring Pyro Pharmaceuticals, Inc.’s patented enzyme identification methodology through its pending acquisition of Pyro Pharmaceuticals. As previously announced, Fero has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro’s capital stock for shares of the Company’s common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009.